Fda purple book dupilumab biosimilar?

Question

Accepted Answer

FDA Purple Book and Dupilumab – Current Status

Topic	Details
What is the FDA Purple Book?	An online database that lists all biologic products (originals & biosimilars) approved by the FDA under the Biologics Price Competition and Innovation Act (BPCIA). It includes product names, manufacturer, approval dates, and whether the product is a “biosimilar” or “interchangeable.”
Dupilumab (brand Dupixent®)	A fully human monoclonal antibody used to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. The original product is approved and listed as a “reference biologic” in the Purple Book.
Dupilumab Biosimilars – Are any listed?	None are currently approved or listed in the Purple Book as of the latest update (early 2026). Several companies have filed Investigational New Drug (IND) applications or Phase III studies, but no biosimilar has received FDA approval yet.
What’s the next step?	Companies that have completed the regulatory pathway (Biologics License Application, BLA) will be added to the Purple Book upon approval. Until that happens, physicians and pharmacists must use the reference product (Dupixent).
Why might a dupilumab biosimilar be delayed?	1. Clinical trial complexity: Dupilumab’s mechanism involves blocking IL‑4 and IL‑13 signaling; demonstrating biosimilarity for immunogenicity and efficacy in multiple indications requires large, well‑controlled trials. 2. Patent & exclusivity: The original product enjoys market exclusivity and patent protection for several years, which can delay biosimilar entry. 3. Manufacturing challenges: Biosimilars must match the reference product’s structural, functional, and safety profile precisely, which is technically demanding.
How to stay updated	1. FDA Purple Book website – check the “Dupilumab” entry or search by manufacturer. 2. FDA’s “Biosimilar and Biosimilar/Interchangeable Approvals” page – lists all newly approved biosimilars. 3. ClinicalTrials.gov – follow ongoing Phase III trials for dupilumab biosimilars.
Implications for clinicians	- Current practice: Use Dupixent® or other FDA‑approved biologics. - Future possibilities: Once a dupilumab biosimilar is approved, formulary decisions and insurance coverage will dictate when it becomes available. - Cost considerations: Biosimilars typically offer lower cost options, potentially improving access.

Bottom line: As of now, the FDA Purple Book lists only the reference dupilumab product; no dupilumab biosimilar has been approved. Keep an eye on the Purple Book and FDA announcements for any new entries.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Fda purple book dupilumab biosimilar?